Pharmacotherapy for rhythm management in elderly patients with atrial fibrillation

Article

Abstract

This review examines pharmacotherapy of rhythm management for atrial fibrillation (AF) in the elderly. There is little research specifically focused on this topic in the elderly but five of the seven randomized controlled trials comparing pharmacologic rate control to pharmacologic rhythm control enrolled patients who can be considered “elderly”. Collectively, these studies showed that the rate control approach was favored for the outcomes of mortality, hospitalization and cost. With respect to stroke and systemic thromboembolism, no clear advantage accrues to either approach and the major therapeutic intervention for stroke prevention is anticoagulation. Rhythm control may be better for relief of symptoms in those who are highly symptomatic but symptoms are usually less problematic in the elderly. Little comparative information is available about use of specific drugs in the elderly but beta blockers are probably the preferred initial therapy for rate control when possible. Although amiodarone is the most effective rhythm control agent, its adverse effect profile suggests it should be reserved for use when other antiarrhythmic drugs fail or are contraindicated. To date, “upstream” or preventive therapies have not been specifically evaluated in the elderly but nebivolol (a beta blocker) does not prevent emergence of AF in elderly patients with heart failure, although it does provide the other salutary benefits of beta blocker therapy seen in younger heart failure patients.

Keywords

Atrial fibrillation Elderly Pharmacotherapy Rhythm management 

References

  1. 1.
    Miyasaka, Y., Barnes, M. E., Gersh, B. J., Cha, S. S., Bailey, K. R., Abhayaratna, W. P. S., et al. (2006). Secular trends in incidence of atrial fibrillation in Olmstead County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation, 114, 119–125.PubMedCrossRefGoogle Scholar
  2. 2.
    Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., et al. (2006). ACC/AHA/ESC 2006 guidelines for management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for Management of Patients with Atrial Fibrillation). Journal of the American College of Cardiology, 48, e149–e246.CrossRefGoogle Scholar
  3. 3.
    Kopecky, S. L., Gersh, B. J., McGoon, M. D., Chu, C. P., Ilstrup, D. M., Chesebro, J. H., et al. (1999). Lone atrial fibrillation in elderly patients: a marker for cardiovascular risk. Archives of Internal Medicine, 159, 1118–1122.PubMedCrossRefGoogle Scholar
  4. 4.
    Levy, S., Maarek, M., Coumel, P., Guize, L., Lekiiffre, J., Medvedowsky, J. L., et al. (1999). Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. Circulation, 99, 3028–3035.PubMedGoogle Scholar
  5. 5.
    Wyse, D. G. (2005). Rate control vs. rhythm control strategies in atrial fibrillation. Progress in Cardiovascular Diseases, 48, 125–138.PubMedCrossRefGoogle Scholar
  6. 6.
    AF-CHF Investigators (2002). Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. American Heart Journal, 144, 597–607.Google Scholar
  7. 7.
    Yamashita, T., Ogawa, S., Aizawa, Y., Atarashi, H., Inoue, H., Ohe, T., et al. (2003). Investigation of the optimal treatment strategy for atrial fibrillation in Japan. The J-RHYTHM (Japanese Rhythm Management Trial for Atrial Fibrillation) study design. Circulation Journal, 67, 738–741.PubMedCrossRefGoogle Scholar
  8. 8.
    Wyse, D. G., Waldo, A. L., DiMarco, J. P., Domanski, M. J., Rosenberg, Y., Schron, E. B., et al. (2002). A comparison of rate control and rhythm control in patients with atrial fibrillation. The New England Journal of Medicine, 347, 1825–1833.PubMedGoogle Scholar
  9. 9.
    Steinberg, J. S., Sadaniantz, A., Kron, J., Krahn, A., Denny, D. M., Daubert, J., et al. (2004). Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation, 109, 1973–1980.PubMedCrossRefGoogle Scholar
  10. 10.
    Olshansky, B., Sami, M., Rubin, A., Kostis, J., Shorofsky, S., Slee, A., et al. (2005). Use of amiodarone for atrial fibrillation in patients with preexisting pulmonary disease in the AFFIRM study. The American Journal of Cardiology, 95, 404–405.PubMedCrossRefGoogle Scholar
  11. 11.
    Akiyama, T., Pawitan, Y., Campbell, W. B., Papa, L., Barker, A. H., Rubbert, P., et al. (1992). Effects of advancing age on efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. Journal of the American Geriatrics Society, 40, 666–672.PubMedGoogle Scholar
  12. 12.
    Bauer, L. A., Black, D., Gensler, A., & Sprinkle, A. (1989). Influence of age, renal function and heart failure on procainamide clearance and n-acetylprocainamide serum concentrations. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 27, 213–216.PubMedGoogle Scholar
  13. 13.
    Sherman, D. G., Kim, S. G., Boop, B. S., Corley, S. D., DiMarco, J. P., Hart, R. G., et al. (2005). Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Archives of Internal Medicine, 165, 1185–1191.PubMedCrossRefGoogle Scholar
  14. 14.
    Mant, J., Hobbs, R., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y. H., et al. (2007). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study): a randomized controlled trial. Lancet, 370, 493–503.PubMedCrossRefGoogle Scholar
  15. 15.
    Hylek, E. M., Evans-Molina, C., Shea, C., Henault, H. E., & Regan, S. (2007). Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation, 115, 2689–2696.PubMedCrossRefGoogle Scholar
  16. 16.
    Jenkins, L. S., Brodsky, M., Schron, E., Chung, M., Rocco, T., Lader, E., et al. (2005). Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. American Heart Journal, 149, 112–120.PubMedCrossRefGoogle Scholar
  17. 17.
    Chung, M. K., Shemanski, L., Sherman, D. G., Greene, H. L., Hogan, D. B., Kellen, J. C., et al. (2005). Functional status in rate- vs. rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) functional status substudy. Journal of the American College of Cardiology, 46, 1891–1899.PubMedCrossRefGoogle Scholar
  18. 18.
    Marshall, D. A., Levy, A. R., Vidaillet, H., Fenwick, E., Slee, A., Blackhouse, G., et al. (2004). Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Annals of Internal Medicine, 141, 653–661.PubMedGoogle Scholar
  19. 19.
    Van Gelder, I. C., Wyse, D. G., Chandler, M. L., Cooper, H. A., Olshansky, B., Hagens, V. E., et al. (2006). Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace, 8, 935–942.PubMedCrossRefGoogle Scholar
  20. 20.
    The AFFIRM First Antiarrhythmic Drug Substudy Investigators (2003). Maintenance of sinus rhythm in patients with atrial fibrillation. An AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology, 42, 20–29.CrossRefGoogle Scholar
  21. 21.
    Olshansky, B., Rosenfeld, L. E., Warner, A. L., Solomon, A. J., O’Neill, G., Sharma, A., et al. (2004). AFFIRM Investigators. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to rate control in atrial fibrillation. Journal of the American College of Cardiology, 43, 1201–1208.PubMedCrossRefGoogle Scholar
  22. 22.
    Wyse, D. G., & Gersh, B. J. (2004). Atrial fibrillation: a perspective: thinking inside and outside the box. Circulation, 109, 3089–3095.PubMedCrossRefGoogle Scholar
  23. 23.
    Engelmann, M. D., & Svendsen, J. H. (2005). Inflammation in the genesis and perpetuation of atrial fibrillation. European Heart Journal, 26, 2083–2092.PubMedCrossRefGoogle Scholar
  24. 24.
    McMurray, J., Kober, L., Robertson, M., Dargie, H., Colucci, W., Lopez-Sendon, J., et al. (2005). Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-infarction Survival in Control in Left Ventricular Dysfunction (CAPRICORN) trial. Journal of the American College of Cardiology, 45, 525–530.PubMedCrossRefGoogle Scholar
  25. 25.
    Nasr, I. A., Bouzamondo, A., Hulot, J. S., Dubourg, O., Le Heuzey, J. Y., & Lechat, P. (2007). Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. European Heart Journal, 28, 457–462.PubMedCrossRefGoogle Scholar
  26. 26.
    Flather, M. D., Shibata, M. C., Coats, A. J., Van Velhuisen, D. J., Parkhomenko, A., Borbola, J., et al. (2005). SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal, 26, 215–225.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Department of Cardiac Sciences, Libin Cardiovascular Institute of AlbertaUniversity of Calgary/Calgary Health RegionCalgaryCanada

Personalised recommendations